Sofosbuvir/velpatasvir regulatory update

EMA accepted and granted accelerated assessment to an MAA from Gilead for once-daily sofosbuvir/velpatasvir to treat chronic HCV genotype 1-6 infection. The company said fixed-dose combination of Sov...